UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
Let's personalize your content